FDA approves Teligent’s generic Clobex lotion

SILVER SPRING, Md. — The Food and Drug Administration has approved Teligent’s generic of Clobex (clobetasol propionate, 0.05%) lotion, the company announced Wednesday. The approval is the company’s sixth in its internally developed pipeline of generics. 

 

“Teligent now has two products which have been approved by the FDA in a first round review, which exceeds current industry average review time periods published by the FDA in October of 2016,” Teligent president and CEO Jason Grenfell-Gardner said. “This is our thirteenth product in our domestic portfolio, and our commercialization team expects to launch this product in the first quarter of 2017."

 

The drug has an addressable market size of approximately $19.5 million, according to QunitilesIMS data from October.